ONC | Jotup

TigerConnect Announces Winners of the Third Annual "Nurses at the Heart of Healthcare" Awards

Retrieved on:

четверг, мая 30, 2024

TigerConnect , healthcare's most trusted clinical collaboration platform, is thrilled to unveil the recipients of the third annual "Nurses at the Heart of Healthcare" Awards.

Key Points:

TigerConnect , healthcare's most trusted clinical collaboration platform, is thrilled to unveil the recipients of the third annual "Nurses at the Heart of Healthcare" Awards.
This year's winners were nominated by nursing leaders who witnessed firsthand the profound dedication and unwavering commitment demonstrated by their peers.
TigerConnect extends heartfelt congratulations to all the recipients of the "Nurses at the Heart of Healthcare" Awards and underscores the importance of supporting nurses' mental and emotional well-being.
For further details about the award program and a comprehensive list of this year's winners, please visit the TigerConnect website at www.tigerconnect.com .

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

Retrieved on:

пятница, мая 24, 2024

With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.

Key Points:

With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts.
The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research.
In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally.
BioSpace concluded: “Several notable trends are shaping the pancreatic cancer market.

American Society for Gastroenterology and Endoscopy Launches Artificial Intelligence Institute at Digestive Disease Week

Retrieved on:

понедельник, мая 20, 2024

The American Society for Gastroenterology and Endoscopy (ASGE) announced today the launch of the Artificial Intelligence Institute for Gastroenterology , a milestone initiative to integrate artificial intelligence (AI) into gastrointestinal (GI) care, enhancing patient outcomes and driving innovation in gastroenterology.

Key Points:

The American Society for Gastroenterology and Endoscopy (ASGE) announced today the launch of the Artificial Intelligence Institute for Gastroenterology , a milestone initiative to integrate artificial intelligence (AI) into gastrointestinal (GI) care, enhancing patient outcomes and driving innovation in gastroenterology.
Unveiled at Digestive Disease Week (DDW), the Institute’s efforts position ASGE as a leading voice in aligning the rapidly evolving landscape of GI healthcare and AI.
The Institute is poised to transform the landscape of GI healthcare by offering transformative benefits for patients and physicians through the fostering of AI technologies.
The Institute is supported by the founding partners, Medtronic, Olympus, Fujifilm and Castle Biosciences.

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on:

четверг, мая 9, 2024

ET

Key Points:

ET
SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced recent operational highlights and financial results for the first quarter ended March 31, 2024.
General and administrative expenses for the first quarter of 2024 were $3.0 million, compared to $3.2 million for the first quarter of 2023.
Research and development expenses for the first quarter of 2024 were $5.7 million, compared to $3.5 million for the first quarter of 2023.
The net loss for the first quarter of 2024 was $6.9 million, compared to a net loss of $6.4 million for the first quarter of 2023.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

четверг, мая 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

четверг, мая 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

четверг, мая 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Retrieved on:

четверг, мая 9, 2024

VANCOUVER, BC, May 9, 2024 /PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's "Cancer Moon Shot" designed to advance cancer research towards a cure. The need for solutions is mounting, as health authorities, on behalf of the United Nations, are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer. As analysts from Custom Market Insights forecast the global cancer immunotherapy market to soar to US$314.4 billion by 2032, expanding at a 7.2% CAGR, the biotech sector continues to advance cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Candel Therapeutics, Inc. (NASDAQ: CADL), AstraZeneca PLC (NASDAQ: AZN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Janux Therapeutics, Inc. (NASDAQ: JANX).

Key Points:

The new cohort is also being supported by a US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN)—an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.
Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.
Janux develops tumor-activated immunotherapies to treat cancer, and has already seen its shares quadruple this year.

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Retrieved on:

четверг, мая 9, 2024

SNF, FOLFIRINOX, DOI, Blood, Pancreatic cancer, Poster, TILS, Immunotherapy, TSX, PR, MD, Tumor microenvironment, AB, ONC, Roche, PDAC, Cancer, Patient, Pancreatic Cancer Action Network, AIO, Medicine, SWI, MMSc, Ethics, PD, Therapy, SAN, Anal cancer, TME, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.

Key Points:

This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).
It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
"Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
"We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.

The Centers Selects Netsmart to Enhance Person-Centered Care Delivery in Arkansas

Retrieved on:

среда, мая 8, 2024

Data Management, Mental Health, Health, Technology, Practice Management, Managed Care, Software, Automation, Human services, EHR, ONC, RCM, SVP, Betty Ford Center, Nursing

Through this collaboration, Netsmart will equip The Centers with the technology and tools designed to support delivery of comprehensive, integrated care to the individuals and families they serve.

Key Points:

Through this collaboration, Netsmart will equip The Centers with the technology and tools designed to support delivery of comprehensive, integrated care to the individuals and families they serve.
By integrating the Netsmart comprehensive suite of solutions, The Centers aims to optimize care delivery and drive positive outcomes for each individual it serves.
As a Certified Community Behavioral Health Clinic (CCBHC) expansion awardee, The Centers will use technology to enhance interoperability, care coordination and streamline key performance metrics ( KPIs ).
“The Centers is leading the way forward by investing in technology and their staff to meet the demands of healthcare delivery and support the wellbeing of the individuals in their care.”